Iravani 1993.

Methods	Randomised, double‐blind Multicentre study: 18 centres across the United States
Participants	Number: 961 women Age: >18 years Inclusion criteria: symptomatic UAC
Interventions	GROUP 1 Single dose fleroxacin (400 mg) GROUP 2 7 days fleroxacin (200 mg once daily) GROUP 3 7 days ciprofloxacin (250 mg twice daily)
Outcomes	Bacteriological Clinical response Adverse events
Notes	Compared group 2 and 3
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Low risk	A ‐ Adequate